Business UpdateJun 22, 2026, 07:07 AM
Can-Fite Publishes Peer-Reviewed Article on Drug Potential
AI Summary
Can-Fite BioPharma Ltd. announced the publication of a peer-reviewed scientific article in the Biomolecules Journal. The article highlights the broad therapeutic potential of its lead drug candidates, Piclidenoson and Namodenoson, which are A3 adenosine receptor (A3AR) agonists. The publication reviews evidence supporting A3AR agonist activity across multiple major diseases, including various cancers, metabolic, autoimmune, and neurodegenerative disorders, validating the company's platform technology.
Key Highlights
- Peer-reviewed article published in Biomolecules Journal on A3 adenosine receptor (A3AR) agonists.
- Article demonstrates broad therapeutic potential of Piclidenoson and Namodenoson.
- A3AR agonists modulate pathways in solid tumors, MASH, autoimmune, inflammatory, and neurodegenerative diseases.
- Piclidenoson is in pivotal Phase 3 study for psoriasis.
- Namodenoson is in Phase 3 for hepatocellular carcinoma and Phase 2b for MASH.
- Publication reinforces A3AR agonists as a platform technology for multiple indications.
Price Impact
More from CANF